Top

Published in:

01-07-2017 | Original Article

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC

Authors: William Sterlacci, Michael Fiegl, Mathias Gugger, Lukas Bubendorf, Spasenija Savic, Alexandar Tzankov

Published in: Virchows Archiv | Issue 1/2017

Abstract

The prevalence of overexpression and amplification of the proto-oncogene mesenchymal epithelial transition (MET) in non-small cell lung cancer (NSCLC) varies greatly in the literature. Since MET is a potential treatment target, knowledge of its prevalence and prognostic importance is crucial. We investigated MET expression and gene status in 735 NSCLC cases using tissue microarrays. Prognostic significance as well as correlations with various clinico-pathological parameters were evaluated. The prevalence of MET overexpression was 17% and MET amplification was present in 2.4% of cases. MET overexpression was found more frequently in adenocarcinomas (and TTF1-positive tumors) and female patients and was also associated with expression of members of the epidermal growth factor receptor (EGFR) signaling cascade. MET amplified tumors tended to express MET more frequently and more intensively. MET expression or gene status did not prove to be relevant prognostic factors. MET may not be an unequivocal prognostic parameter; however, its expression is associated with certain clinico-pathological characteristics and with EGFR and downstream EGFR effectors. This could be an important point for future studies addressing targeted MET therapy and should be considered as a possible means of optimizing the benefit and minimizing undesirable effects.

Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM (1989) Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339:155–156CrossRefPubMed

Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, Comoglio PM (1991) Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6:501–504PubMed

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103CrossRefPubMed

Sacco JJ, Clague MJ (2015) Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. Transl Lung Cancer Res 4:242–252PubMedPubMedCentral

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC (2013) Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105–4114CrossRefPubMedPubMedCentral

Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, Tamura T, Asamura H, Furuta K, Tsuda H (2012) c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 7:331–339CrossRefPubMed

Park S, Koh J, Kim DW, Kim M, Keam B, Kim TM, Jeon YK, Chung DH, Heo DS (2015) MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer 90:381–387CrossRefPubMed

Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455:125–132CrossRefPubMed

Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M (2015) Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer 87:193–200CrossRefPubMed

10.

Travis W, Brambilla E, Müller-Hermelink K, Harris C (2004) Tumours of the lung, pleura, thymus and heart, 3rd edn. IARC Press, Lyon

11.

Travis W, Brambilla E, Burke A, Marx A, Nicholson (2015) A WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. IARC Press, Lyon

12.

Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, Lardinois D, Gugger M, Bubendorf L, Zlobec I, Tapia C (2014) Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer 110:2914–2922CrossRefPubMedPubMedCentral

13.

Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S (2010) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 51:199–212CrossRefPubMed

14.

Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A (2010) Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 5:1325–1336CrossRefPubMed

15.

Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H, Fiegl M, Tzankov A (2012) High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 43:339–349CrossRefPubMed

16.

Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR (2012) Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 7:340–347CrossRefPubMedPubMedCentral

17.

Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler C, Reinmuth N, Huber RM, Thomas M, Zabel P, Rabe KF, Jonigk D, Warth A, Vollmer E, Reck M, Goldmann T (2015) Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol 10:130CrossRefPubMedPubMedCentral

18.

Li A, Niu FY, Han JF, Lou NN, Yang JJ, Zhang XC, Zhou Q, Xie Z, Su J, Zhao N, Huang Y, Wu YL (2015) Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. Lung Cancer 90:375–380CrossRefPubMed

19.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol 34:721–730CrossRefPubMed

Title: MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC
Authors: William Sterlacci
Michael Fiegl
Mathias Gugger
Lukas Bubendorf
Spasenija Savic
Alexandar Tzankov
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 1/2017
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2131-1

At a glance: The STEP trials

Springer Medicine

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

The association between microsatellite instability and lymph node count in colorectal cancer

Clinical and pathological characteristics of gastrointestinal stromal tumor (GIST) metastatic to bone

Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift

HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature

Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome

Invasive lobular carcinoma with extracellular mucin production—a novel pattern of lobular carcinomas of the breast. Clinico-pathological description of eight cases